OphRx is developing eye drops based on noninvasive drug delivery that utilize lyotropic liquid crystals as an alternative to current delivery modalities, such as intra-vitreal injections, used to treat diseases at the back of the eye.

This platform technology can also be used for front-of-the-eye treatments.OphRx is currently in the preclinical stage of development of two product candidates: OPH-101, an alternative topical treatment to intravitreal injections for wet AMD; and OPH-100, a treatment for DES.OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.